Actively Recruiting
Characterization of Chronic Hand Eczema
Led by Dr. Robert Bissonnette · Updated on 2026-04-09
270
Participants Needed
1
Research Sites
326 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Prospective longitudinal study to characterize Choronic Hand Eczema (CHE) subtypes and Atopic Dermatitis (AD) with noninvasive molecular and imaging techniques, and assess changes through time and its association with quality of life.
CONDITIONS
Official Title
Characterization of Chronic Hand Eczema
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Male or female subjects aged 18 to 65 years, inclusive, at the time of consent.
- Willing and able to give informed consent.
- Willing to comply with all study procedures and available for the study duration.
- For CHE subjects: at least 6 months history of chronic hand eczema before screening.
- For CHE subjects: moderate to severe chronic hand eczema with IGA score ≥3 at screening and Day 1.
- For CHE subjects: chronic hand eczema covering ≥0.25% of hand palmar surface at screening and Day 1.
- For CHE subjects: chronic hand eczema categorized into defined subtypes at Day 1.
- For AD subjects: clinically confirmed active atopic dermatitis per Hanifin and Rajka criteria.
- For AD subjects: at least 6 months history of atopic dermatitis with no significant flares in last 4 weeks before screening.
- For AD subjects: moderate to severe atopic dermatitis with vIGA-AD score ≥3 at screening and Day 1.
- For AD subjects: atopic dermatitis covering ≥0.5% of BSA at screening and Day 1.
- For AD subjects: at least one lesion covering ≥0.25% of BSA on forearm at screening and Day 1.
- For healthy volunteers: good general health based on medical history and physical exam.
You will not qualify if you...
- History or presence of skin conditions interfering with study assessments.
- Use of systemic antibiotics within 2 weeks prior to Day 1.
- Use of topical antibiotics within 1 week prior to Day 1.
- Use of topical products with urea or salicylic acid within 1 week prior to Day 1.
- Use of biological agents within 12 weeks or 5 half-lives before Day 1.
- Use of nonbiological investigational products or devices within 4 weeks prior to Day 1.
- Excessive sun exposure, tanning bed use, or planned sunny trips within 4 weeks prior to Day 1.
- Female who is pregnant or planning pregnancy during study.
- For CHE subjects: clinically infected chronic hand eczema.
- For CHE subjects: suspected or proven protein contact dermatitis.
- For CHE subjects: use of doxepin, hydroxyzine, diphenhydramine, or topical treatments affecting CHE within specified times before Day 1.
- For CHE subjects: use of systemic retinoids or systemic treatments affecting CHE within specified times before Day 1.
- Use of dupilumab within 12 weeks prior to Day 1.
- Use of UV-B phototherapy, excimer laser, or PUVA treatment within 4 weeks prior to Day 1.
- For AD subjects: clinically infected AD or lesions on hands/feet at screening or Day 1.
- For AD subjects: IVIg therapy within 12 weeks prior to Day 1.
- For AD subjects: use of medications affecting AD within specified times before Day 1.
- For healthy volunteers: history of atopic dermatitis, allergic rhinitis, or asthma.
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Innovaderm Research
Montreal, Quebec, Canada, H2X 2V1
Actively Recruiting
Research Team
A
Ana Palijan, PhD
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
3
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here